The first day after Lipitor’s patent expired and the news is filled with talk about the measures Pfizer are taking to protect their market share against the generic competition. I had predicted that Big Pharma would be more proactive in promoting their newly off-patent medicines and, while Lipitor may be a special case as the biggest seller, I am sure other companies are watching the outcome with interest, to see how successful they might be in retaining some of that revenue.
Talking of things I wrote about before, I saw that Astrazeneca are putting more funds into their VC arm, MedImmune Ventures. The senior managing director, Ron Laufer, noted that “there is a growing role for corporate VC funds”. All the Big Pharma have these investment vehicles and they are going to be increasingly important with less internal R&D going on.